Following a full submission
AWMSG advice |
||
Status: Recommended | ||
The Minister for Health and Social Services has endorsed AWMSG's recommendation to support the use of enfuvirtide within NHS Wales for the treatment of patients with HIV-1. It has been agreed the following restrictions should apply to its use:
AWMSG would also like to draw the attention of prescribers to the following statement: "AWMSG has concerns that reference in the Patient Product Information Sheet for enfuvirtide of returning vials to the pharmacy may be misinterpreted by patients and could result in them attempting to return a wider range of clinical waste to the pharmacy. Pharmacists, doctors and nurses may find it necessary to draw the attention of patients to the correct way to dispose of their clinical waste." |
||
|
||
Medicine details |
||
Medicine name | enfuvirtide (Fuzeon®) | |
Formulation | 90 mg/ml powder and solvent for solution for injection | |
Reference number | 124 | |
Indication | In combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes: protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens |
|
Company | Roche Products Ltd | |
BNF chapter | Infections | |
Assessment type | Full | |
Status | Recommended | |
AWMSG meeting date | 02/12/2003 | |
Ratification by Welsh Government | 01/03/2004 | |
Date of issue | 28/05/2004 |